Exploration of Targeted Anti-tumor Therapy
Open Exploration Publishing Inc.
About the journal
Exploration of Targeted Anti-tumor Therapy is an open-access journal published by Open Exploration Publishing Inc. in China, publishing in english. It is listed in DOAJ and PUBMED according to the sources read. Declared publication charge: 2,000 USD. Declared review time at DOAJ: 13 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Open Exploration Publishing Inc.
- ISSN
- 2692-3114
- Country
- China
- Languages
- english
- Access
- Open access
- Declared publication charge
- 2,000 USD
- Articles in DOAJ
- 399
- Declared review time
- 13 weeks
- Declared peer-review model
- peer_review
- Official website
- https://www.explorationpub.com/Journals/etat
Index listings
- DOAJ · 2021-04-06
- PUBMED · 2020-02-29
- Indexing
- DOAJ · PUBMED
- APC
- 2,000 USD
- Declared review time (DOAJ)
- 13 weeks — journal-declared only (not measured)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
399
Most recent article
last month
Average review time (journal-declared via DOAJ)
13weeks
Works in OpenAlex
384
Last recorded publication year
2026
h-index
26
i10-index
119
From OpenAlex open data (CC0).
Editorial & policy12
- Last DOAJ review date
- 2025-03-21
- Added to DOAJ
- 2021-04-06
- Declared plagiarism screening
- Declared
- Other fees beyond APC
- No
- Declared digital preservation
- Portico
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- Portico
- Editorial board
- Official page ↗
- Open references deposited at Crossref
- 98%
- ORCID iDs in current deposits
- 94%
- Enrolled in Crossref Similarity Check
- ✓
- Deposits licence metadata at Crossref
- ✓
- APC waiver policy
- View policy
- Peer-review policy
- View policy
Identity & continuity2
- Source type
- journal
- NLM unique ID (PubMed)
- 101770662
Classification2
Subjects (DOAJ)
LCC codes
Subject areas
- Cancer Immunotherapy and Biomarkers
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
- Cancer Cells and Metastasis
- Cancer Cells and Metastasis
Show all subjects (50)
- Lung Cancer Research Studies
- Lung Cancer Research Studies
- Immune cells in cancer
- Immune cells in cancer
- HER2/EGFR in Cancer Research
- Immunotherapy and Immune Responses
- HER2/EGFR in Cancer Research
- Immunotherapy and Immune Responses
- Protein Degradation and Inhibitors
- Protein Degradation and Inhibitors
- Bladder and Urothelial Cancer Treatments
- Bladder and Urothelial Cancer Treatments
- Pancreatic and Hepatic Oncology Research
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Radiomics and Machine Learning in Medical Imaging
- Glioma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Glioma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Peptidase Inhibition and Analysis
- Immune Cell Function and Interaction
- Peptidase Inhibition and Analysis
- Cancer, Hypoxia, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- Multiple Myeloma Research and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Advanced Breast Cancer Therapies
- Multiple Myeloma Research and Treatments
- Ubiquitin and proteasome pathways
- Epigenetics and DNA Methylation
- Inflammatory Biomarkers in Disease Prognosis
- Ubiquitin and proteasome pathways
- Nanoplatforms for cancer theranostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Inflammatory Biomarkers in Disease Prognosis
- Nanoplatforms for cancer theranostics
- Epigenetics and DNA Methylation
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
Keywords (DOAJ)
- cancer
- target therapy
- precision oncology
- diagnosis
- biomarkers
- cancer mechanisms
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ